Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term melanoma. Found 28 abstracts

no pagination
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, Xu X, Morris J, Yin X, Wu H, Xu W, Zheng C, Karakousis GC, Amaravadi RK, Mitchell TC, Almeida FV, Xiao M, Rebecca VW, Wang YJ, Schuchter LM, Herlyn M, Murphy ME, Weeraratna AT. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular cell. 2020 Feb 06;77(3):633-644e5.
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, Xu X, Morris J, Yin X, Wu H, Xu W, Zheng C, Karakousis GC, Amaravadi RK, Mitchell TC, Almeida FV, Xiao M, Rebecca VW, Wang YJ, Schuchter LM, Herlyn M, Murphy ME, Weeraratna AT. Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular cell. 2019 Dec 11;.
Perez-Guijarro E, Day CP, Merlino G, Zaidi MR. Genetically engineered mouse models of melanoma. Cancer. 2017 Jun;123(S11):2089-103.   PMCID: PMC5445933
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07;170(6):1109-1119e10.
van Tuyn J, Jaber-Hijazi F, MacKenzie D, Cole JJ, Mann E, Pawlikowski JS, Singh Rai T, Nelson DM, McBryan T, Ivanov A, Blyth K, Wu H, Milling S, Adams PD. Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, A Candidate Melanoma Suppressor Function. The Journal of investigative dermatology. 2017 Jun 21;137(10):2197-207.   PMCID: PMC5613751
Czyz M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. 2016 Nov 15;7(46):75551-60.   PMCID: PMC5342760
Hooper R, Zaidi MR, Soboloff J. The heterogeneity of store-operated calcium entry in melanoma. Science China Life sciences. 2016 Aug;59(8):764-9.   PMCID: PMC4991353
Ito T, Melamed J, Perle MA, Alukal J. Clear cell sarcoma of the penis: a case report. Am J Clin Exp Urol. 2015 Jan;3(1):43-7.   PMCID: PMC4446382
Allen AM, Pawlicki T, Dong L, Fourkal E, Buyyounouski M, Cengel K, Plastaras J, Bucci MK, Yock TI, Bonilla L, Price R, Harris EE, Konski AA, Stinseymour M. An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. Radiotherapy and Oncology. 2012 Apr;103(1):8-11.   PMCID: not NIH funded
Colt DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):366-400.   PMCID: not NIH funded
Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE. Mucosal Melanoma of the Head and Neck. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):320-38.   PMCID: not NIH Funded
Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomaki K, Amiano P, Apicella C, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB, Fasching PA, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu JJ, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Muller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Silva ID, Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang XS, Wang ZM, Weaver J, Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human molecular genetics. 2012 Dec;21(24):5373-84.   PMCID: PMC 3510753
Coups EJ, Geller AC, Weinstock MA, Heckman CJ, Manne SL. Prevalence and Correlates of Skin Cancer Screening among Middle-aged and Older White Adults in the United States. American Journal of Medicine. 2010 May;123(5):439-45.   PMCID: PMCID: PMC2858071 [Available on 2011/5/1]
Dominguez-Brauer C, Brauer PM, Chen YJ, Pimkina J, Raychaudhuri P. Tumor suppression by ARF Gatekeeper and caretaker. Cell cycle (Georgetown, Tex). 2010 Jan;9(1):86-9.   PMCID: *
Hay J, Coups EJ, Ford J, DiBonaventura M. Exposure to mass media health information, skin cancer beliefs, and sun protection behaviors in a United States probability sample. Journal of the American Academy of Dermatology. 2009 Nov;61(5):783-92.   PMCID: PMC2854488
Palamar M, Thangappan A, Shields CL, Ehya H, Shields JA. Necrotic Choroidal Melanoma With Scleritis and Choroidal Effusion. Cornea. 2009 Apr;28(3):354-6.   PMCID: not NIH funded
Kucher C, Zhang PJ, Pasha T, Elenitsas R, Wu H, Ming ME, Elder DE, Xu XW. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic Nevi. American Journal of Dermatopathology. 2004 Dec;26(6):452-7.
Gude RP, Binda MM, Presas HL, Klein-Szanto AJ, Bonfil RD. Studies on the mechanisms responsible for inhibition of experimental metastasis of B16-F10 murine melanoma by pentoxifylline. Journal of Biomedical Science. 1999 Mar;6(2):133-41.
Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon. Medical Oncology. 1998 Sep;15(3):191-8.
Gunduz K, Shields JA, Shields CL, Eagle RC, Ehya H, McLaughlin W. Lung carcinoma metastatic to the vitreous cavity. Retina-the Journal of Retinal and Vitreous Diseases. 1998 Jan;18(3):285-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term melanoma

melanoma Melanoma malignant-melanoma metabolism pathology tumor genetics radiation therapy wild-type 53 NCCN Clinical Practice Guidelines drug effects interferon expression metastatic melanoma Tumor Microenvironment metastasis radiation-therapy tumor microenvironment biopsy Tumor Cell Line slow-cycling phenotype pharmacology chemotherapy adjuvant therapy cancer risk NCCN Guidelines therapy resistance Wnt5A aged microenvironment irradiation oncolytic immunotherapy gd3 dna-repair in-vivo alpha-IFN scleritis s100 protein necrosis surgical excision melan-a eye senescence kit mutation society phase-iii Poly(ADP-ribose) Polymerase Inhibitors Combined Modality Therapy anti-PD-1 colony-stimulating factor Tumor Suppressor Protein p53 combination human tyrosinase Oncolytic Virotherapy adverse effects lymph node dissection MAP Kinase Kinase Kinases task-force pembrolizumab 1987 arlson me-journal of chronic diseases-v40-p373 Xenograft Model Antitumor Assays Antineoplastic Agents DNA Ligase ATP photon colorectal-cancer effusion choroid biomarkers recombinant interleukin-2 therapy skin cancer beliefs health communication-sun protection behaviors Melanocytes Mutation B16-F10 postoperative radiotherapy brca1 mutation carriers Wnt-5a Protein down-regulation ultraviolet (UV) radiation 1993 n jkl-journal of dermatologic surgery and oncology-v19-p985 interleukin-2 carcinogen metastatic metastases patterns skin retina head and neck cancer clear cell ganglioside uv monoclonal-antibody DNA Repair Ki-67 positron-emission-tomography comorbidity index tumor suppressor ARF-E2F4-XPC-DNA repair neoplasms desmoplastic isolated limb perfusion cancer-cells invitro benign nucleotide excision-repair Piperazines stage-iii melanoma tumor subtypes cell lung-cancer Dacarbazine Animal Disease Models deficiency Biological Models Histones angiogenesis primary-care physicians antigen presentation therapy synthetic lethality Penis PARP1 inhibitor p53 sentinel lymph node mouse models oncolytic viruses t-lymphocytes cooperative-oncology-group tumors mammalian-cells primary cutaneous melanoma Endoplasmic Reticulum Phthalazines mucosal melanoma Sulfonamides Double-Stranded DNA Breaks interleukin 1 cutaneous blocking skull base talimogene laherparepvec Neoplasm Drug Resistance pentoxifylline sclerotic population cell-adhesion margin internet Protein Kinase Inhibitors Screening Melanoma-Skin cancer-Skin examination neck dissection co-morbidity
Last updated on Friday, August 07, 2020